Cell and Gene Outsourcing

  1. The CDMO Value Proposition For Your Autologous Cell Therapy

    This panel session features a decade-long story of partnership in bringing two life-changing gene therapies to market successfully in 2022.

  2. De-Risk Your Path To Clinic With An AAV Suspension Platform

    Build a reliable, de-risked path to the clinic while avoiding unforeseen costs and compliance-related delays with advice from Suparna Sanyal, PhD, Head of Viral Vectors Commercial Development.

  3. Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

    In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

  4. Scalable Suspension LVV Production Platforms

    Review a scalable suspension-based Lenti production platform using a proprietary HEK293T clonal cell line and improvement steps to generate commercially viable therapies from concept to patient.

  5. Advancing Viral Vector Manufacturing: The Importance Of The Cell Line 9/16/2024

    Explore the pivotal role of cell lines in viral vector manufacturing, a complex, multi-step process that has traditionally been both time-consuming and labor-intensive.

  6. An End-To-End Industrialization Roadmap For Autologous Cell Therapy

    Explore specificities and challenges, leveraging automation for scalability with the Cocoon® Platform, and building a vein-to-vein network to achieve ‘just-in-time’ delivery of therapies.

  7. CRISPR Genome Editing Solutions From Discovery To Clinic

    Examine how a partnership leveraging expertise in production for high-quality CRISPR gRNAs as well as cGMP manufacturing is supporting the clinical translation of CRISPR genome editing technologies.

  8. Cell & Gene Therapy Development: Characterization Of Cellular Starting Material 6/21/2024

    Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.

  9. Candidate Screening And Feasibility Studies For Viral Gene Therapies

    Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

  10. Preparing For FDA Pre-Approval Inspection: Quality And Regulatory Topics

    Consider these strategies for meeting quality and regulatory requirements in cell and gene therapies that can also help to identify issues early, reduce risks, and prevent delays and rework.